Moderna Phase III COVID-19 Vaccine Plan To Enroll 30,000 Patients
Executive Summary
The company finalized the Phase III program based on feedback from the US FDA and plans to start the study in July. With a 100 µg dose, Moderna says it can manufacture 500 million doses a year.